Courtagen Snaps Up $8M
Woburn, MA-based Courtagen Life Sciences, has pinned down an $8 million equity investment from 67 backers, an SEC filing shows. The company raised $7 million in Series A funding in August 2010, under its previous name Avantra Biosciences. Courtagen is developing protein biomarker technology for disease detection. The technology was purchased from the now-bankrupt Decision Biomarkers by Courtagen Capital (the parent company of Courtagen Life Sciences) in 2009.